This episode demystifies the process for medical device manufacturers who have U.S. FDA approval and are targeting the Indian market. We clarify that while FDA registration is beneficial, it does not replace the mandatory import license from India's Central Drugs Standard Control Organization (CDSCO). We outline the essential steps, including appointing an Authorized Indian Agent, understanding India's risk-based device classification, and preparing the required Device and Plant Master Files for a successful submission. Key Questions: • Does having U.S. FDA approval mean you can automatically sell your medical device in India? • What is the role of the Central Drugs Standard Control Organization (CDSCO)? • What are the mandatory first steps for a foreign manufacturer to enter the Indian market? • Is an Authorized Indian Agent required, and what are their responsibilities? • What are the Device Master File (DMF) and Plant Master File (PMF)? • How does India classify medical devices, and why does it matter? • What is the typical timeline for obtaining an import license in India? • What critical regulatory deadline passed on October 1, 2023? • How does your existing FDA documentation support your CDSCO application? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.